Physician profile
George C Wang
NPI 1124344767
$12,708.19
in general payments reported to CMS, 2019-2025
59 companies · $2,261 in 2025
The $2,261 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,043 · 2020: $1,149 · 2021: $1,604 · 2022: $1,989 · 2023: $2,359 · 2024: $2,303 · 2025: $2,261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,858 · Education: $65.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,858.39 |
| Education | $65.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,818.20 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $1,060.42 | 2019-2025 | |
| Ucb, INC. | $703.09 | 2019-2025 | Briviact, Rystiggo, Bimzelx |
| Biogen, INC. | $678.03 | 2020-2025 | Vumerity, Tysabri, Spinraza |
| Neurocrine Biosciences, INC. | $603.80 | 2020-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $583.30 | 2020-2023 | Austedo Xr, Austedo |
| Alexion Pharmaceuticals, INC. | $575.93 | 2020-2025 | Ultomiris |
| Acadia Pharmaceuticals INC | $454.07 | 2019-2025 | Nuplazid, Daybue |
| Alnylam Pharmaceuticals INC. | $440.57 | 2022-2025 | Amvuttra, Givlaari |
| Lilly USA, LLC | $417.71 | 2019-2025 | Kisunla, Amyvid |
| Genentech USA, INC. | $417.06 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Pfizer INC. | $364.32 | 2023-2025 | |
| Medtronic, INC. | $345.12 | 2023 | Intellis Adaptivestim |
| Sk Life Science, INC. | $338.03 | 2022-2025 | Xcopri |
| Astrazeneca Pharmaceuticals LP | $331.91 | 2021-2025 | Andexxa, Wainua |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.